AlgiPharma AS is a biopharmaceutical company with primary focus on respiratory diseases, wound healing and other conditions caused by microbial infections and biofilms.
The company’s vision is to be a leading biopharmaceutical company that develops disruptive alginate oligomer technologies in order to fight diseases effectively through innovative therapies.
AlgiPharma has successfully completed a phase 1 clinical trial for its initial drug candidate for respiratory diseases. The drug candidate has proven to be safe and well tolerated in healthy subjects. Our drug candidate for Cystic Fibrosis is currently in a clinical phase 2 trial.
AlgiPharma’s wound healing lead product candidate is entering proof-of-concept studies during spring 2012 under a grant from the US Department of Defense.
|
|
|
